Gut microbiome and metabolome signatures in liver cirrhosis-related complications
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Shifts in the gut microbiota and metabolites are interrelated with liver cirrhosis progression and complications. However, causal relationships have not been evaluated comprehensively. Here, we identified complication-dependent gut microbiota and metabolic signatures in patients with liver cirrhosis. Methods: Microbiome taxonomic profiling was performed on 194 stool samples (52 controls and 142 cirrhosis patients) via V3-V4 16S rRNA sequencing. Next, 51 samples (17 controls and 34 cirrhosis patients) were selected for fecal metabolite profiling via gas chromatography mass spectrometry and liquid chromatography coupled to timeof- flight mass spectrometry. Correlation analyses were performed targeting the gut-microbiota, metabolites, clinical parameters, and presence of complications (varices, ascites, peritonitis, encephalopathy, hepatorenal syndrome, hepatocellular carcinoma, and deceased). Results: Veillonella bacteria, Ruminococcus gnavus, and Streptococcus pneumoniae are cirrhosis-related microbiotas compared with control group. Bacteroides ovatus, Clostridium symbiosum, Emergencia timonensis, Fusobacterium varium, and Hungatella_uc were associated with complications in the cirrhosis group. The areas under the receiver operating characteristic curve (AUROCs) for the diagnosis of cirrhosis, encephalopathy, hepatorenal syndrome, and deceased were 0.863, 0.733, 0.71, and 0.69, respectively. The AUROCs of mixed microbial species for the diagnosis of cirrhosis and complication were 0.808 and 0.847, respectively. According to the metabolic profile, 5 increased fecal metabolites in patients with cirrhosis were biomarkers (AUROC >0.880) for the diagnosis of cirrhosis and complications. Clinical markers were significantly correlated with the gut microbiota and metabolites. Conclusions: Cirrhosis-dependent gut microbiota and metabolites present unique signatures that can be used as noninvasive biomarkers for the diagnosis of cirrhosis and its complications.
Abstract
Background/Aims: Shifts in the gut microbiota and metabolites are interrelated with liver cirrhosis progression and complications. However, causal relationships have not been evaluated comprehensively. Here, we identified complication-dependent gut microbiota and metabolic signatures in patients with liver cirrhosis. Methods: Microbiome taxonomic profiling was performed on 194 stool samples (52 controls and 142 cirrhosis patients) via V3-V4 16S rRNA sequencing. Next, 51 samples (17 controls and 34 cirrhosis patients) were selected for fecal metabolite profiling via gas chromatography mass spectrometry and liquid chromatography coupled to timeof- flight mass spectrometry. Correlation analyses were performed targeting the gut-microbiota, metabolites, clinical parameters, and presence of complications (varices, ascites, peritonitis, encephalopathy, hepatorenal syndrome, hepatocellular carcinoma, and deceased). Results: Veillonella bacteria, Ruminococcus gnavus, and Streptococcus pneumoniae are cirrhosis-related microbiotas compared with control group. Bacteroides ovatus, Clostridium symbiosum, Emergencia timonensis, Fusobacterium varium, and Hungatella_uc were associated with complications in the cirrhosis group. The areas under the receiver operating characteristic curve (AUROCs) for the diagnosis of cirrhosis, encephalopathy, hepatorenal syndrome, and deceased were 0.863, 0.733, 0.71, and 0.69, respectively. The AUROCs of mixed microbial species for the diagnosis of cirrhosis and complication were 0.808 and 0.847, respectively. According to the metabolic profile, 5 increased fecal metabolites in patients with cirrhosis were biomarkers (AUROC >0.880) for the diagnosis of cirrhosis and complications. Clinical markers were significantly correlated with the gut microbiota and metabolites. Conclusions: Cirrhosis-dependent gut microbiota and metabolites present unique signatures that can be used as noninvasive biomarkers for the diagnosis of cirrhosis and its complications.
참고문헌 (50)
- Solé C, "Alterations in gut microbiome in cirrhosis as assessed by quantitative metagenomics : relationship with acute-on-chronic liver failure and prognosis", Gastroenterology, 160, pp.206~218 (2021)
- Bajaj JS, "Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy", Hepatology, 62, pp.1260~1271 (2015)
- Lee G, "Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD", Nat Commun, 11, pp.4982~ (2020)
- Ganesan R, "Microbiome and metabolomics in alcoholic liver disease", Clin Mol Hepatol, 28, pp.580~582 (2022)
- Bajaj JS, "Serum levels of metabolites produced by intestinal microbes and lipid moieties independently associated with acute-on-chronic liver failure and death in patients with cirrhosis", Gastroenterology, 159, pp.1715~1730 (2020)
- Tonon M, "Acute on chronic liver failure in cirrhosis", Clin Mol Hepatol, 28, pp.273~275 (2022)
- Acharya C, "Altered microbiome in patients with cirrhosis and complications", Clin Gastroenterol Hepatol, 17, pp.307~321 (2019)
- Philips CA, "Identification and analysis of gut microbiota and functional metabolism in decompensated cirrhosis with infection", J Clin Transl Hepatol, 11, pp.15~25 (2023)
- Trebicka J, "Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure", Nat Rev Gastroenterol Hepatol, 18, pp.167~180 (2021)
- Seo B, "Roseburia spp. abundance associates with alcohol consumption in humans and its administration ameliorates alcoholic fatty liver in mice", Cell Host Microbe, 27, pp.25~40 (2020)
- Zhang C, "Assessment of the safety and probiotic properties of Roseburia intestinalis : a potential"next generation probiotic"", Front Microbiol, 13, pp.973046~ (2022)
- Ruuskanen MO, "Links between gut microbiome composition and fatty liver disease in a large population sample", Gut Microbes, 13, pp.1~22 (2021)
- Wang K, "Gut microbiota as prognosis markers for patients with HBV-related acute-on-chronic liver failure", Gut Microbes, 13, pp.1~15 (2021)
- Bajaj JS, "Multiple bacterial virulence factors focused on adherence and biofilm formation associate with outcomes in cirrhosis", Gut Microbes, 13, pp.1993584~ (2021)
- Iebba V, "Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy", Sci Rep, 8, pp.8210~ (2018)
- Kwan SY, "Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease", Hepatology, 75, pp.955~967 (2022)
- Elshaghabee FMF, "Effect of oral administration of weissella confusa on fecal and plasma ethanol concentrations, lipids and glucose metabolism in wistar rats fed high fructose and fat diet", Hepat Med, 12, pp.93~106 (2020)
- Spanu D, "Hepatocellular carcinoma and microbiota : implications for clinical management and treatment", World J Hepatol, 14, pp.1319~1332 (2022)
- Jie Z, "A consortium of three-bacteria isolated from human feces inhibits formation of atherosclerotic deposits and lowers lipid levels in a mouse model", iScience, 26, pp.106960~ (2023)
- Kwon YK, "Clostridium paraputrificum septicemia and liver abscess", World J Hepatol, 10, pp.388~395 (2018)
- Kaneko M, "Presumptive complicating Clostridium paraputrificum bacteremia as a presenting manifestation in a patient with undiagnosed ulcerative colitis followed by acute colonic pseudo-obstruction", IDCases, 31, pp.e01652~ (2023)
- Gautam M, "Streptococcus salivarius bacteremia and spontaneous bacterial peritonitis in liver transplantation candidates", Liver Transpl, 13, pp.1582~1588 (2007)
- Erwes T, "A novel case of Raoultella bacteremia secondary to liver abscess formation following transarterial chemoembolization", IDCases, 24, pp.e01150~ (2021)
- Rao Y, "Gut Akkermansia muciniphila ameliorates metabolic dysfunctionassociated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis", Gut Microbes, 13, pp.1~19 (2021)
- Zhu X, "Akkermansia muciniphila, which is enriched in the gut microbiota by metformin, improves cognitive function in aged mice by reducing the proinflammatory cytokine interleukin-6", Microbiome, 11, pp.120~ (2023)
- Nie K, "Roseburia intestinalis : a beneficial gut organism from the discoveries in genus and species", Front Cell Infect Microbiol, 11, pp.757718~ (2021)
- Shen Z, "Roseburia intestinalis stimulates TLR5-dependent intestinal immunity against Crohn’s disease", EBioMedicine, 85, pp.104285~ (2022)
- Testerman T, "Insights from shotgun metagenomics into bacterial species and metabolic pathways associated with NAFLD in obese youth", Hepatol Commun, 6, pp.1962~1974 (2022)
- Tanoue T, "A defined commensal consortium elicits CD8 T cells and anti-cancer immunity", Nature, 565, pp.600~605 (2019)
- Moreau R, "Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF", J Hepatol, 72, pp.688~701 (2020)
- Sehgal R, "Indole-3-propionic acid, a gut-derived tryptophan metabolite, associates with hepatic fibrosis", Nutrients, 13, pp.3509~ (2021)
- Zhao ZH, "Sodium butyrate supplementation inhibits hepatic steatosis by stimulating liver kinase B1 and insulin-induced gene", Cell Mol Gastroenterol Hepatol, 12, pp.857~871 (2021)
- Amiri P, "Role of butyrate, a gut microbiota derived metabolite, in cardiovascular diseases : a comprehensive narrative review", Front Pharmacol, 12, pp.837509~ (2021)
- Bridgeman SC, "Butyrate generated by gut microbiota and its therapeutic role in metabolic syndrome", Pharmacol Res, 160, pp.105174~ (2020)
- Sanada S, "Intestinal microbial metabolite stercobilin involvement in the chronic inflammation of ob", ob mice, 2020, pp.10, 6479~
- Sekera ER, "Depletion of stercobilin in fecal matter from a mouse model of autism spectrum disorders", Metabolomics, 13, pp.132~ (2017)
- Cervantes-Barragan L, "Lactobacillus reuteri induces gut intraepithelial CD4+CD8αα+ T cells", Science, 357, pp.806~810 (2017)
- Mendes BG, "From intestinal dysbiosis to alcoholassociated liver disease", Clin Mol Hepatol, 26, pp.595~605 (2020)
- Yoo HJ, "Liver cirrhosis patients who had normal liver function before liver cirrhosis development have the altered metabolic profiles before the disease occurrence compared to healthy controls", Front Physiol, 10, pp.1421~ (2019)
- Bjørndal B, "Associations between fatty acid oxidation, hepatic mitochondrial function, and plasma acylcarnitine levels in mice", Nutr Metab(Lond), 15, pp.10~ (2018)
- Jepsen P, "MELD remains the best predictor of mortality in outpatients with cirrhosis and severe ascites", Aliment Pharmacol Ther, 52, pp.492~499 (2020)
- Lisman T, "Haemostatic alterations and management of haemostasis in patients with cirrhosis", J Hepatol, 76, pp.1291~1305 (2022)
- Dong B, "Aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in patients with autoimmune hepatitis : a meta-analysis", Front Immunol, 13, pp.892454~ (2022)
- Lee HA, "Direct bilirubin is more valuable than total bilirubin for predicting prognosis in patients with liver cirrhosis", Gut Liver, 15, pp.599~605 (2021)
- Stoffers P, "Diagnostic and prognostic significance of cell death markers in patients with cirrhosis and acute decompensation", PLoS One, 17, pp.e0263989~ (2022)
- China L, "A randomized trial of albumin infusions in hospitalized patients with cirrhosis", N Engl J Med, 384, pp.808~817 (2021)
- De Filippis F, "Outlook on nextgeneration probiotics from the human gut", Cell Mol Life Sci, 79, pp.76~ (2022)
- Min BH, "Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation", Gut Microbes, 16, pp.2307568~ (2024)
- Yan M, "Gut liver brain axis in diseases : the implications for therapeutic interventions", Signal Transduct Target Ther, 8, pp.443~ (2023)
- Eom JA, "Gut-microbiota prompt activation of natural killer cell on alcoholic liver disease", Gut Microbes, 15, pp.2281014~ (2023)